Tag Archives: biosimilars

European Physicians Have "Insufficient Knowledge of Biosimilars"

European physicians have insufficient knowledge of biosimilars, according to a survey carried out by the Alliance for Safe Biologic Medicines (ASBM). Only 22% of physicians consider themselves “very familiar” with this  category of medicines, and while a majority (54%) have a “basic understanding” of biosimilars, 24% of participants could not define or have not heard about […]
Posted in Biotech, Europe, Events, Gene therapy, Global | Also tagged , , | Leave a comment

AbbVie, Amgen, and Roche Most Exposed to Biosimilar Competition

While biosimilar products have been launched in Asia and Europe, they are at least three years away in the US, according to a new report on the global biosimilar drugs market.
Posted in Biotech, Gene therapy | Also tagged , , , | Leave a comment

HTAs Impact on Biosimilars in Europe

Cuts in healthcare costs due to post-recession austerity programs mean favorable Health Technology Assessments (HTAs) are becoming crucial to the successful market launch of pharmaceuticals in Europe. HTAs backing reimbursement can be vital for new innovative medicines and also for biosimilars. EUnetHTA has been stepping up its efforts to achieve more consistency in the methodology […]
Posted in Europe, Regulatory | Also tagged , , , , | Leave a comment

FDA Guidances, OIG Investigations to Shape Drug Marketing, Research

Marketers may see further advice from the Food and Drug Administration in the coming year that clarifies how they can use social media. Priority topics:  presenting risk and benefit information in limited space; correcting independent/third party misinformation about a drug or medical device; and appropriate use of links, according to the agenda for the Center […]
Posted in Advertising, Biotech, E-Media, FDA, Legal, pricing, Regulatory, social media | Also tagged , , , , , , | Leave a comment

Global Biosimilars Market to Soar to $24 Billion by 2019

Frost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019 LONDON – 29th January 2014 – The imminent entry of several companies, including big pharma, small biotech and generic […]
Posted in Biotech, Europe, Global, Strategy | Also tagged , | 1 Comment
  • Categories

  • Meta